|
1
|
Picci P: Osteosarcoma (osteogenic
sarcoma). Orphanet J Rare Dis. 2(6)2007.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Ottaviani G and Jaffe N: The epidemiology
of osteosarcoma. Cancer Treat Res. 152:3–13. 2009.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Liu W, Zhang X, Liu P, Shen X, Lan T, Li
W, Jiang Q, Xie X and Huang H: Effects of berberine on matrix
accumulation and NF-kappa B signal pathway in alloxan-induced
diabetic mice with renal injury. Eur J Pharmacol. 638:150–155.
2010.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Yoshida K, Okamoto M, Aoki K, Takahashi J
and Saito N: A Review of T-Cell Related Therapy for Osteosarcoma.
Int J Mol Sci. 21(4877)2020.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Punzalan M and Hyden G: The role of
physical therapy and occupational therapy in the rehabilitation of
pediatric and adolescent patients with osteosarcoma. Cancer Treat
Res. 152:367–384. 2009.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Daw NC, Chou AJ, Jaffe N, Rao BN, Billups
CA, Rodriguez-Galindo C, Meyers PA and Huh WW: Recurrent
osteosarcoma with a single pulmonary metastasis: A
multi-institutional review. Br J Cancer. 112:278–282.
2015.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Meazza C and Scanagatta P: Metastatic
osteosarcoma: A challenging multidisciplinary treatment. Expert Rev
Anticancer Ther. 16:543–556. 2016.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Sun HH, Chen XY, Cui JQ, Zhou ZM and Guo
KJ: Prognostic factors to survival of patients with chondroblastic
osteosarcoma. Medicine (Baltimore). 97(e12636)2018.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Imura Y, Takenaka S, Kakunaga S, Nakai T,
Wakamatsu T, Outani H, Tanaka T, Tamiya H, Oshima K, Hamada K, et
al: Survival analysis of elderly patients with osteosarcoma. Int
Orthop. 43:1741–1747. 2019.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Liao YX, Yu HY, Lv JY, Cai YR, Liu F, He
ZM and He SS: Targeting autophagy is a promising therapeutic
strategy to overcome chemoresistance and reduce metastasis in
osteosarcoma. Int J Oncol. 55:1213–1222. 2019.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Lagos-Quintana M, Rauhut R, Lendeckel W
and Tuschl T: Identification of novel genes coding for small
expressed RNAs. Science. 294:853–858. 2001.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Qiao W, Cao N and Yang L: MicroRNA-154
inhibits the growth and metastasis of gastric cancer cells by
directly targeting MTDH. Oncol Lett. 14:3268–3274. 2017.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Yang ZQ, Wu CA and Cheng YX: Prognostic
value of microRNA-133a expression and its clinicopathologic
significance in non-small cell lung cancer: a comprehensive study
based on meta-analysis and the TCGA database. Oncol Res Treat.
41:762–768. 2018.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Li C, Zhang J, Ma Z, Zhang F and Yu W:
miR-19b serves as a prognostic biomarker of breast cancer and
promotes tumor progression through PI3K/AKT signaling pathway.
OncoTargets Ther. 11:4087–4095. 2018.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Wang L, Xu M, Lu P and Zhou F:
microRNA-769 is downregulated in colorectal cancer and inhibits
cancer progression by directly targeting cyclin-dependent kinase 1.
OncoTargets Ther. 11:9013–9025. 2018.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Ji Q, Xu X, Song Q, Xu Y, Tai Y, Goodman
SB, Bi W, Xu M, Jiao S, Maloney WJ, et al: miR-223-3p inhibits
human osteosarcoma metastasis and progression by directly targeting
CDH6. Mol Ther. 26:1299–1312. 2018.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Cai W, Xu Y, Yin J, Zuo W and Su Z:
miR-552-5p facilitates osteosarcoma cell proliferation and
metastasis by targeting WIF1. Exp Ther Med. 17:3781–3788.
2019.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Yu M, Zhang X, Li H, Zhang P and Dong W:
MicroRNA-588 is downregulated and may have prognostic and
functional roles in human breast cancer. Med Sci Monit.
23:5690–5696. 2017.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Zhao N, Lin T, Zhao C, Zhao S, Zhou S and
Li Y: MicroRNA-588 is upregulated in human prostate cancer with
prognostic and functional implications. J Cell Biochem: Oct 5, 2017
(Epub ahead of print).
|
|
20
|
Zhou X and Xu M, Guo Y, Ye L, Long L, Wang
H, Tan P and Xu M: MicroRNA-588 regulates invasion, migration and
epithelial-mesenchymal transition via targeting EIF5A2 pathway in
gastric cancer. Cancer Manag Res. 10:5187–5197. 2018.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Qian L, Lin L, Du Y, Hao X, Zhao Y and Liu
X: MicroRNA-588 suppresses tumor cell migration and invasion by
targeting GRN in lung squamous cell carcinoma. Mol Med Rep.
14:3021–3028. 2016.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Chen G, Yu W, Li Z, Wang Q, Yang Q, Du Z,
Zhang G and Song Y: Potential regulatory effects of miR-182-3p in
osteosarcoma via targeting EBF2. BioMed Res Int.
2019(4897905)2019.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Wang SY, Hu HZ, Qing XC, Zhang ZC and Shao
ZW: Recent advances of drug delivery nanocarriers in osteosarcoma
treatment. J Cancer. 11:69–82. 2020.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Qiu S, Tao L and Zhu Y: Marital Status and
Survival in Osteosarcoma Patients: An Analysis of the Surveillance,
Epidemiology, and End Results (SEER) Database. Med Sci Monit.
25:8190–8203. 2019.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Bushati N and Cohen SM: microRNA
functions. Annu Rev Cell Dev Biol. 23:175–205. 2007.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Mohr AM and Mott JL: Overview of microRNA
biology. Semin Liver Dis. 35:3–11. 2015.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Wang J, Liu S, Shi J, Li J, Wang S, Liu H,
Zhao S, Duan K, Pan X and Yi Z: The Role of miRNA in the Diagnosis,
Prognosis, and Treatment of Osteosarcoma. Cancer Biother
Radiopharm. 34:605–613. 2019.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Shi YK and Guo YH: MiR-139-5p suppresses
osteosarcoma cell growth and invasion through regulating DNMT1.
Biochem Biophys Res Commun. 503:459–466. 2018.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Iorio MV and Croce CM: MicroRNA
dysregulation in cancer: Diagnostics, monitoring and therapeutics.
A comprehensive review. EMBO Mol Med. 4:143–159. 2012.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Shi YX, Ye BL, Hu BR and Ruan XJ:
Expression of miR-1294 is downregulated and predicts a poor
prognosis in gastric cancer. Eur Rev Med Pharmacol Sci.
22:5525–5530. 2018.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Chen Y, Gao DY and Huang L: In vivo
delivery of miRNAs for cancer therapy: Challenges and strategies.
Adv Drug Deliv Rev. 81:128–141. 2015.PubMed/NCBI View Article : Google Scholar
|
